These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19845683)

  • 1. Mediators and receptors in the resolution of inflammation: drug targeting opportunities.
    Stewart AG
    Br J Pharmacol; 2009 Oct; 158(4):933-5. PubMed ID: 19845683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel omega -- 3-derived local mediators in anti-inflammation and resolution.
    Serhan CN
    Pharmacol Ther; 2005 Jan; 105(1):7-21. PubMed ID: 15626453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases.
    Yacoubian S; Serhan CN
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):570-9; quiz 1 p following 589. PubMed ID: 17906612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular regulators of resolution of inflammation: potential therapeutic targets in the reproductive system.
    Hutchinson JL; Rajagopal SP; Sales KJ; Jabbour HN
    Reproduction; 2011 Jul; 142(1):15-28. PubMed ID: 21490125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A twist in anti-inflammation: annexin 1 acts via the lipoxin A4 receptor.
    Gavins FN; Sawmynaden P; Chatterjee BE; Perretti M
    Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):211-9. PubMed ID: 15982865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.
    Serhan CN
    J Periodontol; 2008 Aug; 79(8 Suppl):1520-6. PubMed ID: 18673006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor.
    Dalli J; Consalvo AP; Ray V; Di Filippo C; D'Amico M; Mehta N; Perretti M
    J Immunol; 2013 Jun; 190(12):6478-87. PubMed ID: 23686496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics.
    Serhan CN; Chiang N
    Rheum Dis Clin North Am; 2004 Feb; 30(1):69-95. PubMed ID: 15061569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor.
    Perretti M; D'Acquisto F
    Inflamm Allergy Drug Targets; 2006 Apr; 5(2):107-14. PubMed ID: 16613569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins.
    Serhan CN; Chiang N
    ScientificWorldJournal; 2002 Jan; 2():169-204. PubMed ID: 12806051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.
    Serhan CN; Chiang N; Van Dyke TE
    Nat Rev Immunol; 2008 May; 8(5):349-61. PubMed ID: 18437155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annexin-A1: Therapeutic Potential in Microvascular Disease.
    Purvis GSD; Solito E; Thiemermann C
    Front Immunol; 2019; 10():938. PubMed ID: 31114582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases.
    Perucci LO; Sugimoto MA; Gomes KB; Dusse LM; Teixeira MM; Sousa LP
    Expert Opin Ther Targets; 2017 Sep; 21(9):879-896. PubMed ID: 28786708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoxins in inflammation.
    Sachdeva S; Saluja H; Mani A; Phadnaik MB; Mani S
    Clin Hemorheol Microcirc; 2022; 82(3):201-216. PubMed ID: 35147530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.
    Perretti M; D'Acquisto F
    Nat Rev Immunol; 2009 Jan; 9(1):62-70. PubMed ID: 19104500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.
    Serhan CN
    Annu Rev Immunol; 2007; 25():101-37. PubMed ID: 17090225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory drugs, eicosanoids and the annexin A1/FPR2 anti-inflammatory system.
    Yazid S; Norling LV; Flower RJ
    Prostaglandins Other Lipid Mediat; 2012 Aug; 98(3-4):94-100. PubMed ID: 22123264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination.
    Norling LV; Serhan CN
    J Intern Med; 2010 Jul; 268(1):15-24. PubMed ID: 20497301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer.
    Janakiram NB; Rao CV
    Curr Mol Med; 2009 Jun; 9(5):565-79. PubMed ID: 19601807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.
    Serhan CN
    FASEB J; 2017 Apr; 31(4):1273-1288. PubMed ID: 28087575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.